CN101506180B - 人蛋白酪氨酸磷酸酶抑制剂及使用方法 - Google Patents
人蛋白酪氨酸磷酸酶抑制剂及使用方法 Download PDFInfo
- Publication number
- CN101506180B CN101506180B CN2007800309846A CN200780030984A CN101506180B CN 101506180 B CN101506180 B CN 101506180B CN 2007800309846 A CN2007800309846 A CN 2007800309846A CN 200780030984 A CN200780030984 A CN 200780030984A CN 101506180 B CN101506180 B CN 101506180B
- Authority
- CN
- China
- Prior art keywords
- phenyl
- ethyl
- thiazole
- base
- sulfonic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims abstract description 79
- 108090000144 Human Proteins Proteins 0.000 title description 4
- 102000003839 Human Proteins Human genes 0.000 title description 4
- 239000003806 protein tyrosine phosphatase inhibitor Substances 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 109
- 239000000203 mixture Substances 0.000 claims abstract description 78
- 230000001105 regulatory effect Effects 0.000 claims abstract description 28
- -1 isobutyl- Chemical group 0.000 claims description 324
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 284
- 229910052739 hydrogen Inorganic materials 0.000 claims description 193
- 239000001257 hydrogen Substances 0.000 claims description 193
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 152
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 123
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 101
- 239000002253 acid Substances 0.000 claims description 95
- 125000000437 thiazol-2-yl group Chemical group [H]C1=C([H])N=C(*)S1 0.000 claims description 93
- 238000002360 preparation method Methods 0.000 claims description 78
- BEHLMOQXOSLGHN-UHFFFAOYSA-N benzenamine sulfate Chemical compound OS(=O)(=O)NC1=CC=CC=C1 BEHLMOQXOSLGHN-UHFFFAOYSA-N 0.000 claims description 77
- 230000004862 vasculogenesis Effects 0.000 claims description 72
- 150000002431 hydrogen Chemical class 0.000 claims description 69
- 229910052760 oxygen Inorganic materials 0.000 claims description 51
- 239000001301 oxygen Substances 0.000 claims description 51
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 45
- 125000000217 alkyl group Chemical group 0.000 claims description 44
- 125000001072 heteroaryl group Chemical group 0.000 claims description 44
- 150000003839 salts Chemical class 0.000 claims description 39
- 230000008569 process Effects 0.000 claims description 37
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 32
- 210000001519 tissue Anatomy 0.000 claims description 32
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims description 30
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 29
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims description 27
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 27
- 201000010099 disease Diseases 0.000 claims description 25
- 238000011282 treatment Methods 0.000 claims description 23
- 125000004429 atom Chemical group 0.000 claims description 20
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 20
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 20
- 230000012010 growth Effects 0.000 claims description 16
- 229910052736 halogen Inorganic materials 0.000 claims description 16
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 15
- 150000002367 halogens Chemical class 0.000 claims description 13
- 125000000623 heterocyclic group Chemical group 0.000 claims description 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 12
- 125000004208 3-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C([H])C(*)=C1[H] 0.000 claims description 8
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 8
- 230000000302 ischemic effect Effects 0.000 claims description 8
- 230000017423 tissue regeneration Effects 0.000 claims description 8
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea group Chemical group NC(=O)N XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 8
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 claims description 7
- 150000001408 amides Chemical class 0.000 claims description 7
- 229910052757 nitrogen Inorganic materials 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 6
- 230000001939 inductive effect Effects 0.000 claims description 5
- 210000002027 skeletal muscle Anatomy 0.000 claims description 5
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 claims description 4
- 206010008190 Cerebrovascular accident Diseases 0.000 claims description 4
- 208000018262 Peripheral vascular disease Diseases 0.000 claims description 4
- 208000006011 Stroke Diseases 0.000 claims description 4
- 208000029078 coronary artery disease Diseases 0.000 claims description 4
- 229910001882 dioxygen Inorganic materials 0.000 claims description 4
- 125000005842 heteroatom Chemical group 0.000 claims description 4
- 208000031225 myocardial ischemia Diseases 0.000 claims description 4
- 125000001617 2,3-dimethoxy phenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C(OC([H])([H])[H])=C1[H] 0.000 claims description 3
- 125000004211 3,5-difluorophenyl group Chemical group [H]C1=C(F)C([H])=C(*)C([H])=C1F 0.000 claims description 3
- 230000010478 bone regeneration Effects 0.000 claims description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 3
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 claims description 3
- 125000000335 thiazolyl group Chemical group 0.000 claims description 3
- JOWXBGIZDALBJW-UHFFFAOYSA-N 3h-dioxepine Chemical compound C1OOC=CC=C1 JOWXBGIZDALBJW-UHFFFAOYSA-N 0.000 claims description 2
- OMEARSOPYMXZCH-IBGZPJMESA-N [4-[(2s)-2-[[2-(2,3-dimethoxyphenyl)acetyl]amino]-2-(4-ethyl-1,3-thiazol-2-yl)ethyl]phenyl]sulfamic acid Chemical compound CCC1=CSC([C@H](CC=2C=CC(NS(O)(=O)=O)=CC=2)NC(=O)CC=2C(=C(OC)C=CC=2)OC)=N1 OMEARSOPYMXZCH-IBGZPJMESA-N 0.000 claims description 2
- YCSBQALUBMTXON-INIZCTEOSA-N [4-[(2s)-2-[[2-(2,4-dimethyl-1,3-thiazol-5-yl)acetyl]amino]-2-(4-methyl-1,3-thiazol-2-yl)ethyl]phenyl]sulfamic acid Chemical compound CC1=CSC([C@H](CC=2C=CC(NS(O)(=O)=O)=CC=2)NC(=O)CC2=C(N=C(C)S2)C)=N1 YCSBQALUBMTXON-INIZCTEOSA-N 0.000 claims description 2
- XRAJFIBLSSTKML-SFHVURJKSA-N [4-[(2s)-2-[[2-(2,5-dimethyl-1,3-thiazol-4-yl)acetyl]amino]-2-(4-ethyl-1,3-thiazol-2-yl)ethyl]phenyl]sulfamic acid Chemical compound CCC1=CSC([C@H](CC=2C=CC(NS(O)(=O)=O)=CC=2)NC(=O)CC2=C(SC(C)=N2)C)=N1 XRAJFIBLSSTKML-SFHVURJKSA-N 0.000 claims description 2
- UMEVMMJAIZFKAX-IBGZPJMESA-N [4-[(2s)-2-[[2-(3,4-dimethoxyphenyl)acetyl]amino]-2-(4-ethyl-1,3-thiazol-2-yl)ethyl]phenyl]sulfamic acid Chemical compound CCC1=CSC([C@H](CC=2C=CC(NS(O)(=O)=O)=CC=2)NC(=O)CC=2C=C(OC)C(OC)=CC=2)=N1 UMEVMMJAIZFKAX-IBGZPJMESA-N 0.000 claims description 2
- ZFJPXJKLQKCVQX-IBGZPJMESA-N [4-[(2s)-2-[[2-(3-fluorophenyl)acetyl]amino]-2-(2-thiophen-2-yl-1,3-thiazol-4-yl)ethyl]phenyl]sulfamic acid Chemical compound C1=CC(NS(=O)(=O)O)=CC=C1C[C@@H](C=1N=C(SC=1)C=1SC=CC=1)NC(=O)CC1=CC=CC(F)=C1 ZFJPXJKLQKCVQX-IBGZPJMESA-N 0.000 claims description 2
- 229940095102 methyl benzoate Drugs 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 abstract description 18
- 101000738772 Homo sapiens Receptor-type tyrosine-protein phosphatase beta Proteins 0.000 abstract description 16
- 230000033115 angiogenesis Effects 0.000 abstract description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical class OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 86
- 238000005160 1H NMR spectroscopy Methods 0.000 description 74
- 239000000047 product Substances 0.000 description 65
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 63
- 239000000243 solution Substances 0.000 description 61
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 56
- 239000003153 chemical reaction reagent Substances 0.000 description 53
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 51
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 50
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 41
- 239000011541 reaction mixture Substances 0.000 description 41
- 238000003756 stirring Methods 0.000 description 33
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 28
- 150000002148 esters Chemical class 0.000 description 28
- 239000011734 sodium Substances 0.000 description 28
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 27
- 0 C*(C)C(CC(CC1)[C@]1C1*)SC1SC=CC**(C)C(*)*C1NCC(C2CC2)SC1 Chemical compound C*(C)C(CC(CC1)[C@]1C1*)SC1SC=CC**(C)C(*)*C1NCC(C2CC2)SC1 0.000 description 26
- AYDQIZKZTQHYIY-UHFFFAOYSA-N OC(=O)C1(C)CC(C(O)=O)=CC=C1 Chemical compound OC(=O)C1(C)CC(C(O)=O)=CC=C1 AYDQIZKZTQHYIY-UHFFFAOYSA-N 0.000 description 25
- 235000019439 ethyl acetate Nutrition 0.000 description 25
- 239000000376 reactant Substances 0.000 description 23
- 238000005406 washing Methods 0.000 description 23
- 238000001914 filtration Methods 0.000 description 21
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 20
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 18
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 17
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 17
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 16
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 15
- 150000003863 ammonium salts Chemical class 0.000 description 15
- 239000007864 aqueous solution Substances 0.000 description 15
- 210000004204 blood vessel Anatomy 0.000 description 15
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 14
- 206010028980 Neoplasm Diseases 0.000 description 14
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 14
- 239000000741 silica gel Substances 0.000 description 14
- 229910002027 silica gel Inorganic materials 0.000 description 14
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 13
- 239000012299 nitrogen atmosphere Substances 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- LSBDFXRDZJMBSC-UHFFFAOYSA-N 2-phenylacetamide Chemical compound NC(=O)CC1=CC=CC=C1 LSBDFXRDZJMBSC-UHFFFAOYSA-N 0.000 description 12
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 12
- 206010052428 Wound Diseases 0.000 description 12
- 208000027418 Wounds and injury Diseases 0.000 description 12
- 230000003197 catalytic effect Effects 0.000 description 12
- 239000010410 layer Substances 0.000 description 12
- 125000003118 aryl group Chemical group 0.000 description 11
- 125000001309 chloro group Chemical group Cl* 0.000 description 11
- 239000012044 organic layer Substances 0.000 description 11
- 229920006395 saturated elastomer Polymers 0.000 description 11
- XBXCNNQPRYLIDE-UHFFFAOYSA-N tert-butylcarbamic acid Chemical compound CC(C)(C)NC(O)=O XBXCNNQPRYLIDE-UHFFFAOYSA-N 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- 238000000746 purification Methods 0.000 description 10
- 229910052799 carbon Inorganic materials 0.000 description 9
- 239000000284 extract Substances 0.000 description 9
- 238000010992 reflux Methods 0.000 description 9
- 239000000725 suspension Substances 0.000 description 9
- 125000004432 carbon atom Chemical group C* 0.000 description 8
- 238000001035 drying Methods 0.000 description 8
- 125000002140 imidazol-4-yl group Chemical group [H]N1C([H])=NC([*])=C1[H] 0.000 description 8
- ZWZVWGITAAIFPS-UHFFFAOYSA-N thiophosgene Chemical compound ClC(Cl)=S ZWZVWGITAAIFPS-UHFFFAOYSA-N 0.000 description 8
- 239000003981 vehicle Substances 0.000 description 8
- 206010061876 Obstruction Diseases 0.000 description 7
- 150000001412 amines Chemical class 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 210000003725 endotheliocyte Anatomy 0.000 description 7
- 238000000605 extraction Methods 0.000 description 7
- 230000035876 healing Effects 0.000 description 7
- 125000000962 organic group Chemical group 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 6
- 208000030507 AIDS Diseases 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 208000031953 Hereditary hemorrhagic telangiectasia Diseases 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 206010053648 Vascular occlusion Diseases 0.000 description 6
- 125000003545 alkoxy group Chemical group 0.000 description 6
- 125000000304 alkynyl group Chemical group 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000012141 concentrate Substances 0.000 description 6
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 239000012074 organic phase Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 125000002769 thiazolinyl group Chemical group 0.000 description 6
- HPGGPRDJHPYFRM-UHFFFAOYSA-J tin(iv) chloride Chemical compound Cl[Sn](Cl)(Cl)Cl HPGGPRDJHPYFRM-UHFFFAOYSA-J 0.000 description 6
- 208000021331 vascular occlusion disease Diseases 0.000 description 6
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- 230000017531 blood circulation Effects 0.000 description 5
- 230000001684 chronic effect Effects 0.000 description 5
- 125000004093 cyano group Chemical group *C#N 0.000 description 5
- 206010012601 diabetes mellitus Diseases 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 5
- 201000000306 sarcoidosis Diseases 0.000 description 5
- 125000000547 substituted alkyl group Chemical group 0.000 description 5
- IJAYMUFRRBWQPU-UHFFFAOYSA-N (2-methyl-1,3-thiazol-4-yl)methanesulfonyl chloride Chemical compound CC1=NC(CS(Cl)(=O)=O)=CS1 IJAYMUFRRBWQPU-UHFFFAOYSA-N 0.000 description 4
- 238000004293 19F NMR spectroscopy Methods 0.000 description 4
- WYKHSBAVLOPISI-UHFFFAOYSA-N 2-phenyl-1,3-thiazole Chemical compound C1=CSC(C=2C=CC=CC=2)=N1 WYKHSBAVLOPISI-UHFFFAOYSA-N 0.000 description 4
- CBBVPEYJGLWZEO-UHFFFAOYSA-N 4-[1-isothiocyanato-2-(4-nitrophenyl)ethyl]-2-phenyl-1,3-thiazole Chemical compound C1=CC([N+](=O)[O-])=CC=C1CC(N=C=S)C1=CSC(C=2C=CC=CC=2)=N1 CBBVPEYJGLWZEO-UHFFFAOYSA-N 0.000 description 4
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 4
- 102000013275 Somatomedins Human genes 0.000 description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 4
- 239000005864 Sulphur Substances 0.000 description 4
- 206010046851 Uveitis Diseases 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 4
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 4
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
- FKRCODPIKNYEAC-UHFFFAOYSA-N ethyl propionate Chemical compound CCOC(=O)CC FKRCODPIKNYEAC-UHFFFAOYSA-N 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 125000005647 linker group Chemical group 0.000 description 4
- 208000002780 macular degeneration Diseases 0.000 description 4
- 239000008164 mustard oil Substances 0.000 description 4
- FDPIMTJIUBPUKL-UHFFFAOYSA-N pentan-3-one Chemical compound CCC(=O)CC FDPIMTJIUBPUKL-UHFFFAOYSA-N 0.000 description 4
- 230000002792 vascular Effects 0.000 description 4
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 3
- TUTKIFZMDPIQEL-UHFFFAOYSA-N 3-(3-phenylphenyl)propanamide Chemical compound NC(CCC=1C=C(C=CC=1)C1=CC=CC=C1)=O TUTKIFZMDPIQEL-UHFFFAOYSA-N 0.000 description 3
- VYIBCOSBNVFEIW-UHFFFAOYSA-N 3-phenylpropanamide Chemical compound NC(=O)CCC1=CC=CC=C1 VYIBCOSBNVFEIW-UHFFFAOYSA-N 0.000 description 3
- XBQADBXCNQPHHY-NSHDSACASA-N 33305-77-0 Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)CC1=CC=C([N+]([O-])=O)C=C1 XBQADBXCNQPHHY-NSHDSACASA-N 0.000 description 3
- 206010009900 Colitis ulcerative Diseases 0.000 description 3
- 208000011231 Crohn disease Diseases 0.000 description 3
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 3
- 201000002563 Histoplasmosis Diseases 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 3
- 201000004681 Psoriasis Diseases 0.000 description 3
- 201000006704 Ulcerative Colitis Diseases 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 3
- 230000036770 blood supply Effects 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 125000005843 halogen group Chemical group 0.000 description 3
- 125000001183 hydrocarbyl group Chemical group 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- DMEKUKDWAIXWSL-UHFFFAOYSA-N n,n-dimethyl-7-nitro-9h-fluoren-2-amine Chemical compound [O-][N+](=O)C1=CC=C2C3=CC=C(N(C)C)C=C3CC2=C1 DMEKUKDWAIXWSL-UHFFFAOYSA-N 0.000 description 3
- NGDQPHPYBDYZNQ-UHFFFAOYSA-N n-[1-(2-cyclopropyl-1,3-thiazol-4-yl)-2-(4-nitrophenyl)ethyl]-4-[(3-methoxyphenyl)methyl]-1,3-thiazol-2-amine Chemical compound COC1=CC=CC(CC=2N=C(NC(CC=3C=CC(=CC=3)[N+]([O-])=O)C=3N=C(SC=3)C3CC3)SC=2)=C1 NGDQPHPYBDYZNQ-UHFFFAOYSA-N 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 3
- 206010055031 vascular neoplasm Diseases 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- RAIPHJJURHTUIC-UHFFFAOYSA-N 1,3-thiazol-2-amine Chemical compound NC1=NC=CS1 RAIPHJJURHTUIC-UHFFFAOYSA-N 0.000 description 2
- CCXQVBSQUQCEEO-UHFFFAOYSA-N 1-bromobutan-2-one Chemical compound CCC(=O)CBr CCXQVBSQUQCEEO-UHFFFAOYSA-N 0.000 description 2
- MCTWTZJPVLRJOU-UHFFFAOYSA-N 1-methyl-1H-imidazole Chemical compound CN1C=CN=C1 MCTWTZJPVLRJOU-UHFFFAOYSA-N 0.000 description 2
- 125000006017 1-propenyl group Chemical group 0.000 description 2
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 2
- WFPMUFXQDKMVCO-UHFFFAOYSA-N 2-(3-chlorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC(Cl)=C1 WFPMUFXQDKMVCO-UHFFFAOYSA-N 0.000 description 2
- ZYHQGITXIJDDKC-UHFFFAOYSA-N 2-[2-(2-aminophenyl)ethyl]aniline Chemical group NC1=CC=CC=C1CCC1=CC=CC=C1N ZYHQGITXIJDDKC-UHFFFAOYSA-N 0.000 description 2
- 125000004807 2-methylethylene group Chemical group [H]C([H])([H])C([H])([*:2])C([H])([H])[*:1] 0.000 description 2
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 2
- BZQGAPWJKAYCHR-UHFFFAOYSA-N 3,3-diphenylpropanoic acid Chemical compound C=1C=CC=CC=1C(CC(=O)O)C1=CC=CC=C1 BZQGAPWJKAYCHR-UHFFFAOYSA-N 0.000 description 2
- CBBVPEYJGLWZEO-INIZCTEOSA-N 4-[(1s)-1-isothiocyanato-2-(4-nitrophenyl)ethyl]-2-phenyl-1,3-thiazole Chemical compound C1=CC([N+](=O)[O-])=CC=C1C[C@H](N=C=S)C1=CSC(C=2C=CC=CC=2)=N1 CBBVPEYJGLWZEO-INIZCTEOSA-N 0.000 description 2
- KMQLIDDEQAJAGJ-UHFFFAOYSA-N 4-oxo-4-phenylbutyric acid Chemical compound OC(=O)CCC(=O)C1=CC=CC=C1 KMQLIDDEQAJAGJ-UHFFFAOYSA-N 0.000 description 2
- PMZBHPUNQNKBOA-UHFFFAOYSA-N 5-methylbenzene-1,3-dicarboxylic acid Chemical compound CC1=CC(C(O)=O)=CC(C(O)=O)=C1 PMZBHPUNQNKBOA-UHFFFAOYSA-N 0.000 description 2
- 102100028187 ATP-binding cassette sub-family C member 6 Human genes 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 208000009137 Behcet syndrome Diseases 0.000 description 2
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 description 2
- YXHKONLOYHBTNS-UHFFFAOYSA-N Diazomethane Chemical compound C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 description 2
- 239000005977 Ethylene Substances 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 206010051151 Hyperviscosity syndrome Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 208000016604 Lyme disease Diseases 0.000 description 2
- 206010025412 Macular dystrophy congenital Diseases 0.000 description 2
- 208000035719 Maculopathy Diseases 0.000 description 2
- 206010062207 Mycobacterial infection Diseases 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- 208000010191 Osteitis Deformans Diseases 0.000 description 2
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 2
- 208000027868 Paget disease Diseases 0.000 description 2
- 208000004788 Pars Planitis Diseases 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
- 208000002158 Proliferative Vitreoretinopathy Diseases 0.000 description 2
- 201000004613 Pseudoxanthoma elasticum Diseases 0.000 description 2
- 206010038848 Retinal detachment Diseases 0.000 description 2
- 206010038910 Retinitis Diseases 0.000 description 2
- 206010038933 Retinopathy of prematurity Diseases 0.000 description 2
- 206010038934 Retinopathy proliferative Diseases 0.000 description 2
- 206010039361 Sacroiliitis Diseases 0.000 description 2
- 206010040943 Skin Ulcer Diseases 0.000 description 2
- QIOZLISABUUKJY-UHFFFAOYSA-N Thiobenzamide Chemical compound NC(=S)C1=CC=CC=C1 QIOZLISABUUKJY-UHFFFAOYSA-N 0.000 description 2
- 201000005485 Toxoplasmosis Diseases 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 206010047663 Vitritis Diseases 0.000 description 2
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 2
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 2
- 125000003368 amide group Chemical group 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 210000001715 carotid artery Anatomy 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 238000011097 chromatography purification Methods 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 2
- LEQAOMBKQFMDFZ-UHFFFAOYSA-N glyoxal Chemical compound O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 208000013653 hyalitis Diseases 0.000 description 2
- 238000005984 hydrogenation reaction Methods 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- CFHGBZLNZZVTAY-UHFFFAOYSA-N lawesson's reagent Chemical compound C1=CC(OC)=CC=C1P1(=S)SP(=S)(C=2C=CC(OC)=CC=2)S1 CFHGBZLNZZVTAY-UHFFFAOYSA-N 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 206010025135 lupus erythematosus Diseases 0.000 description 2
- 208000027202 mammary Paget disease Diseases 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 208000027531 mycobacterial infectious disease Diseases 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 208000001491 myopia Diseases 0.000 description 2
- 230000004379 myopia Effects 0.000 description 2
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 2
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 208000021971 neovascular inflammatory vitreoretinopathy Diseases 0.000 description 2
- 150000002828 nitro derivatives Chemical class 0.000 description 2
- 230000000050 nutritive effect Effects 0.000 description 2
- 125000001715 oxadiazolyl group Chemical group 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 238000002600 positron emission tomography Methods 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 235000015320 potassium carbonate Nutrition 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- 230000006785 proliferative vitreoretinopathy Effects 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 208000023558 pseudoxanthoma elasticum (inherited or acquired) Diseases 0.000 description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 230000004264 retinal detachment Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000002603 single-photon emission computed tomography Methods 0.000 description 2
- 231100000019 skin ulcer Toxicity 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 2
- 239000012265 solid product Substances 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 125000003107 substituted aryl group Chemical group 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 208000006379 syphilis Diseases 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- JOCRHSHXHVVIFS-UHFFFAOYSA-N thiophene-2-carbothioic s-acid Chemical compound SC(=O)C1=CC=CS1 JOCRHSHXHVVIFS-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- 201000007790 vitelliform macular dystrophy Diseases 0.000 description 2
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 description 1
- ZPQOPVIELGIULI-UHFFFAOYSA-N 1,3-dichlorobenzene Chemical compound ClC1=CC=CC(Cl)=C1 ZPQOPVIELGIULI-UHFFFAOYSA-N 0.000 description 1
- UEMGWPRHOOEKTA-UHFFFAOYSA-N 1,3-difluorobenzene Chemical compound FC1=CC=CC(F)=C1 UEMGWPRHOOEKTA-UHFFFAOYSA-N 0.000 description 1
- HMVYYTRDXNKRBQ-UHFFFAOYSA-N 1,3-thiazole-4-carboxylic acid Chemical compound OC(=O)C1=CSC=N1 HMVYYTRDXNKRBQ-UHFFFAOYSA-N 0.000 description 1
- BWFLKAMDZBXOCS-IBGZPJMESA-N 1-benzyl-3-[(1s)-1-(4-ethyl-1,3-thiazol-2-yl)-2-(4-nitrophenyl)ethyl]urea Chemical compound CCC1=CSC([C@H](CC=2C=CC(=CC=2)[N+]([O-])=O)NC(=O)NCC=2C=CC=CC=2)=N1 BWFLKAMDZBXOCS-IBGZPJMESA-N 0.000 description 1
- LGNGNRKVHLNCIZ-IBGZPJMESA-N 1-benzyl-3-[(1s)-2-(4-nitrophenyl)-1-(2-thiophen-2-yl-1,3-thiazol-4-yl)ethyl]urea Chemical compound C1=CC([N+](=O)[O-])=CC=C1C[C@@H](C=1N=C(SC=1)C=1SC=CC=1)NC(=O)NCC1=CC=CC=C1 LGNGNRKVHLNCIZ-IBGZPJMESA-N 0.000 description 1
- QSSXJPIWXQTSIX-UHFFFAOYSA-N 1-bromo-2-methylbenzene Chemical compound CC1=CC=CC=C1Br QSSXJPIWXQTSIX-UHFFFAOYSA-N 0.000 description 1
- 125000001478 1-chloroethyl group Chemical group [H]C([H])([H])C([H])(Cl)* 0.000 description 1
- 125000003070 2-(2-chlorophenyl)ethyl group Chemical group [H]C1=C([H])C(Cl)=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- GKNCPTLOPRDYMH-UHFFFAOYSA-N 2-bromo-1-(2-methoxyphenyl)ethanone Chemical compound COC1=CC=CC=C1C(=O)CBr GKNCPTLOPRDYMH-UHFFFAOYSA-N 0.000 description 1
- 125000002856 2-fluorophenylethyl group Chemical group [H]C1=C([H])C(F)=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- SBBWXWWNOVUXHH-KRWDZBQOSA-N 2-methyl-5-[[(1S)-2-(4-nitrophenyl)-1-(2-phenyl-1,3-thiazol-4-yl)ethyl]amino]-1,3-thiazole-4-carboxylic acid Chemical compound CC=1SC(=C(N1)C(=O)O)N[C@@H](CC1=CC=C(C=C1)[N+](=O)[O-])C=1N=C(SC1)C1=CC=CC=C1 SBBWXWWNOVUXHH-KRWDZBQOSA-N 0.000 description 1
- GBTDBGCFBSEIRV-UHFFFAOYSA-N 2-methylpentan-2-yl carbamate Chemical compound CCCC(C)(C)OC(N)=O GBTDBGCFBSEIRV-UHFFFAOYSA-N 0.000 description 1
- 125000004362 3,4,5-trichlorophenyl group Chemical group [H]C1=C(Cl)C(Cl)=C(Cl)C([H])=C1* 0.000 description 1
- LJGHYPLBDBRCRZ-UHFFFAOYSA-N 3-(3-aminophenyl)sulfonylaniline Chemical group NC1=CC=CC(S(=O)(=O)C=2C=C(N)C=CC=2)=C1 LJGHYPLBDBRCRZ-UHFFFAOYSA-N 0.000 description 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- ZNOLNAPJKOYTHY-UHFFFAOYSA-N 4-(4-(P-Chlorophenyl)-2,5,6-Trihydropyridino)-4'-Fluorobutyrophenone Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CC=C(C=2C=CC(Cl)=CC=2)CC1 ZNOLNAPJKOYTHY-UHFFFAOYSA-N 0.000 description 1
- AQBBZYVPKBIILN-UHFFFAOYSA-N 4-(chloromethyl)-2-methyl-1,3-thiazole Chemical compound CC1=NC(CCl)=CS1 AQBBZYVPKBIILN-UHFFFAOYSA-N 0.000 description 1
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 1
- NTKREJUXCBFWFR-KRWDZBQOSA-N 4-[(2s)-2-isothiocyanato-2-(4-nitrophenyl)ethyl]-2-phenyl-1,3-thiazole Chemical compound C1=CC([N+](=O)[O-])=CC=C1[C@@H](N=C=S)CC1=CSC(C=2C=CC=CC=2)=N1 NTKREJUXCBFWFR-KRWDZBQOSA-N 0.000 description 1
- VSAWBBYYMBQKIK-UHFFFAOYSA-N 4-[[3,5-bis[(3,5-ditert-butyl-4-hydroxyphenyl)methyl]-2,4,6-trimethylphenyl]methyl]-2,6-ditert-butylphenol Chemical compound CC1=C(CC=2C=C(C(O)=C(C=2)C(C)(C)C)C(C)(C)C)C(C)=C(CC=2C=C(C(O)=C(C=2)C(C)(C)C)C(C)(C)C)C(C)=C1CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 VSAWBBYYMBQKIK-UHFFFAOYSA-N 0.000 description 1
- 125000004860 4-ethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004861 4-isopropyl phenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 206010000358 Accelerated hypertension Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical group CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 1
- 102100022987 Angiogenin Human genes 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 206010003497 Asphyxia Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- FBLYZBJIDFMYNN-JTQLQIEISA-N C(N)(OC(C[C@H](CC1=CC=C(C=C1)[N+](=O)[O-])C(N)=S)(C)C)=O Chemical compound C(N)(OC(C[C@H](CC1=CC=C(C=C1)[N+](=O)[O-])C(N)=S)(C)C)=O FBLYZBJIDFMYNN-JTQLQIEISA-N 0.000 description 1
- RGHPCLZJAFCTIK-UHFFFAOYSA-N CC1NCCC1 Chemical compound CC1NCCC1 RGHPCLZJAFCTIK-UHFFFAOYSA-N 0.000 description 1
- XPHBPTGUODREJE-LBPRGKRZSA-N CCc1c[s]c([C@H](Cc(cc2)ccc2O)N)n1 Chemical compound CCc1c[s]c([C@H](Cc(cc2)ccc2O)N)n1 XPHBPTGUODREJE-LBPRGKRZSA-N 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- XLSZMDLNRCVEIJ-UHFFFAOYSA-N Cc1c[nH]cn1 Chemical compound Cc1c[nH]cn1 XLSZMDLNRCVEIJ-UHFFFAOYSA-N 0.000 description 1
- XKVUYEYANWFIJX-UHFFFAOYSA-N Cc1n[nH]cc1 Chemical compound Cc1n[nH]cc1 XKVUYEYANWFIJX-UHFFFAOYSA-N 0.000 description 1
- PMDHIMMPXRSDML-UHFFFAOYSA-N Cc1nccc(C(O)=O)c1 Chemical compound Cc1nccc(C(O)=O)c1 PMDHIMMPXRSDML-UHFFFAOYSA-N 0.000 description 1
- 241000370738 Chlorion Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Natural products OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 206010017577 Gait disturbance Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 101000606537 Homo sapiens Receptor-type tyrosine-protein phosphatase delta Proteins 0.000 description 1
- 101001087394 Homo sapiens Tyrosine-protein phosphatase non-receptor type 1 Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 208000035901 Ischaemic ulcer Diseases 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- HBBGRARXTFLTSG-UHFFFAOYSA-N Lithium ion Chemical compound [Li+] HBBGRARXTFLTSG-UHFFFAOYSA-N 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 101100481410 Mus musculus Tek gene Proteins 0.000 description 1
- PMDCZENCAXMSOU-UHFFFAOYSA-N N-ethylacetamide Chemical compound CCNC(C)=O PMDCZENCAXMSOU-UHFFFAOYSA-N 0.000 description 1
- PTUSICOEEPWBGO-HNNXBMFYSA-N N[C@@H](Cc(cc1)ccc1[N+]([O-])=O)c1c[s]c(-c2ccccc2)n1 Chemical compound N[C@@H](Cc(cc1)ccc1[N+]([O-])=O)c1c[s]c(-c2ccccc2)n1 PTUSICOEEPWBGO-HNNXBMFYSA-N 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 1
- 102100039666 Receptor-type tyrosine-protein phosphatase delta Human genes 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
- 206010043540 Thromboangiitis obliterans Diseases 0.000 description 1
- 102100033001 Tyrosine-protein phosphatase non-receptor type 1 Human genes 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- OFLXLNCGODUUOT-UHFFFAOYSA-N acetohydrazide Chemical compound C\C(O)=N\N OFLXLNCGODUUOT-UHFFFAOYSA-N 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000004644 alkyl sulfinyl group Chemical group 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 239000002870 angiogenesis inducing agent Substances 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 108010072788 angiogenin Proteins 0.000 description 1
- 108010066999 angiogenin receptor Proteins 0.000 description 1
- 230000003527 anti-angiogenesis Effects 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 210000002376 aorta thoracic Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000002565 arteriole Anatomy 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 238000009739 binding Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 229910001451 bismuth ion Inorganic materials 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 231100000481 chemical toxicant Toxicity 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- 210000003711 chorioallantoic membrane Anatomy 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- UKJLNMAFNRKWGR-UHFFFAOYSA-N cyclohexatrienamine Chemical group NC1=CC=C=C[CH]1 UKJLNMAFNRKWGR-UHFFFAOYSA-N 0.000 description 1
- RZVSTEQRCQKJIC-UHFFFAOYSA-N cyclopropanecarbothioic s-acid Chemical compound SC(=O)C1CC1 RZVSTEQRCQKJIC-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 230000005059 dormancy Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 239000003269 fluorescent indicator Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000003784 fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229940015043 glyoxal Drugs 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229920006258 high performance thermoplastic Polymers 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 229940088592 immunologic factor Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 125000001905 inorganic group Chemical group 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-M iodide Chemical compound [I-] XMBWDFGMSWQBCA-UHFFFAOYSA-M 0.000 description 1
- 229940006461 iodide ion Drugs 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000007654 ischemic lesion Effects 0.000 description 1
- ZNJZPZDIWLJZTD-UHFFFAOYSA-N isocyanomethyl acetate Chemical compound CC(=O)OC[N+]#[C-] ZNJZPZDIWLJZTD-UHFFFAOYSA-N 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 201000002818 limb ischemia Diseases 0.000 description 1
- 229910001416 lithium ion Inorganic materials 0.000 description 1
- OVEHNNQXLPJPPL-UHFFFAOYSA-N lithium;n-propan-2-ylpropan-2-amine Chemical compound [Li].CC(C)NC(C)C OVEHNNQXLPJPPL-UHFFFAOYSA-N 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 210000000713 mesentery Anatomy 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- NGDQPHPYBDYZNQ-QFIPXVFZSA-N n-[(1s)-1-(2-cyclopropyl-1,3-thiazol-4-yl)-2-(4-nitrophenyl)ethyl]-4-[(3-methoxyphenyl)methyl]-1,3-thiazol-2-amine Chemical compound COC1=CC=CC(CC=2N=C(N[C@@H](CC=3C=CC(=CC=3)[N+]([O-])=O)C=3N=C(SC=3)C3CC3)SC=2)=C1 NGDQPHPYBDYZNQ-QFIPXVFZSA-N 0.000 description 1
- UCNRIVIOUVGFFO-UHFFFAOYSA-N n-[1-(4-ethyl-1,3-thiazol-2-yl)-2-(4-nitrophenyl)ethyl]-2-phenylacetamide Chemical compound CCC1=CSC(C(CC=2C=CC(=CC=2)[N+]([O-])=O)NC(=O)CC=2C=CC=CC=2)=N1 UCNRIVIOUVGFFO-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 238000011369 optimal treatment Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- SIOXPEMLGUPBBT-UHFFFAOYSA-N picolinic acid Chemical compound OC(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-N 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 230000001023 pro-angiogenic effect Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 102000037983 regulatory factors Human genes 0.000 description 1
- 108091008025 regulatory factors Proteins 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000003019 stabilising effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 125000005415 substituted alkoxy group Chemical group 0.000 description 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-M sulfamate Chemical compound NS([O-])(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-M 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 150000003557 thiazoles Chemical class 0.000 description 1
- DENPQNAWGQXKCU-UHFFFAOYSA-N thiophene-2-carboxamide Chemical class NC(=O)C1=CC=CS1 DENPQNAWGQXKCU-UHFFFAOYSA-N 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 210000004127 vitreous body Anatomy 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
序号 | L | R1 | R2 | R3 |
1 | -C(O)CH2- | 苯基 | -CH3 | -H |
2 | -C(O)CH2- | 2-氟苯基 | -CH3 | -H |
3 | -C(O)CH2- | 3-氟苯基 | -CH3 | -H |
4 | -C(O)CH2- | 4-氟苯基 | -CH3 | -H |
5 | -C(O)CH2- | 2,3-二氟苯基 | -CH3 | -H |
6 | -C(O)CH2- | 3,4-二氟苯基 | -CH3 | -H |
7 | -C(O)CH2- | 3,5-二氟苯基 | -CH3 | -H |
8 | -C(O)CH2- | 2-氯苯基 | -CH3 | -H |
9 | -C(O)CH2- | 3-氯苯基 | -CH3 | -H |
10 | -C(O)CH2- | 4-氯苯基 | -CH3 | -H |
11 | -C(O)CH2- | 2,3-二氯苯基 | -CH3 | -H |
12 | -C(O)CH2- | 3,4-二氯苯基 | -CH3 | -H |
13 | -C(O)CH2- | 3,5-二氯苯基 | -CH3 | -H |
14 | -C(O)CH2- | 2-羟基苯基 | -CH3 | -H |
15 | -C(O)CH2- | 3-羟基苯基 | -CH3 | -H |
16 | -C(O)CH2- | 4-羟基苯基 | -CH3 | -H |
17 | -C(O)CH2- | 2-甲氧基苯基 | -CH3 | -H |
18 | -C(O)CH2- | 3-甲氧基苯基 | -CH3 | -H |
19 | -C(O)CH2- | 4-甲氧基苯基 | -CH3 | -H |
20 | -C(O)CH2- | 2,3-二甲氧基苯基 | -CH3 | -H |
21 | -C(O)CH2- | 3,4-二甲氧基苯基 | -CH3 | -H |
22 | -C(O)CH2- | 3,5-二甲氧基苯基 | -CH3 | -H |
23 | -C(O)CH2- | 苯基 | -CH2CH3 | -H |
24 | -C(O)CH2- | 2-氟苯基 | -CH2CH3 | -H |
25 | -C(O)CH2- | 3-氟苯基 | -CH2CH3 | -H |
26 | -C(O)CH2- | 4-氟苯基 | -CH2CH3 | -H |
27 | -C(O)CH2- | 2,3-二氟苯基 | -CH2CH3 | -H |
28 | -C(O)CH2- | 3,4-二氟苯基 | -CH2CH3 | -H |
29 | -C(O)CH2- | 3,5-二氟苯基 | -CH2CH3 | -H |
30 | -C(O)CH2- | 2-氯苯基 | -CH2CH3 | -H |
31 | -C(O)CH2- | 3-氯苯基 | -CH2CH3 | -H |
32 | -C(O)CH2- | 4-氯苯基 | -CH2CH3 | -H |
33 | -C(O)CH2- | 2,3-二氯苯基 | -CH2CH3 | -H |
34 | -C(O)CH2- | 3,4-二氯苯基 | -CH2CH3 | -H |
35 | -C(O)CH2- | 3,5-二氯苯基 | -CH2CH3 | -H |
36 | -C(O)CH2- | 2-羟基苯基 | -CH2CH3 | -H |
37 | -C(O)CH2- | 3-羟基苯基 | -CH2CH3 | -H |
38 | -C(O)CH2- | 4-羟基苯基 | -CH2CH3 | -H |
39 | -C(O)CH2- | 2-甲氧基苯基 | -CH2CH3 | -H |
40 | -C(O)CH2- | 3-甲氧基苯基 | -CH2CH3 | -H |
41 | -C(O)CH2- | 4-甲氧基苯基 | -CH2CH3 | -H |
42 | -C(O)CH2- | 2,3-二甲氧基苯基 | -CH2CH3 | -H |
43 | -C(O)CH2- | 3,4-二甲氧基苯基 | -CH2CH3 | -H |
44 | -C(O)CH2- | 3,5-二甲氧基苯基 | -CH2CH3 | -H |
45 | -C(O)CH2CH2- | 苯基 | -CH3 | -H |
46 | -C(O)CH2CH2- | 2-氟苯基 | -CH3 | -H |
47 | -C(O)CH2CH2- | 3-氟苯基 | -CH3 | -H |
48 | -C(O)CH2CH2- | 4-氟苯基 | -CH3 | -H |
49 | -C(O)CH2CH2- | 2,3-二氟苯基 | -CH3 | -H |
50 | -C(O)CH2CH2- | 3,4-二氟苯基 | -CH3 | -H |
51 | -C(O)CH2CH2- | 3,5-二氟苯基 | -CH3 | -H |
52 | -C(O)CH2CH2- | 2-氯苯基 | -CH3 | -H |
53 | -C(O)CH2CH2- | 3-氯苯基 | -CH3 | -H |
54 | -C(O)CH2CH2- | 4-氯苯基 | -CH3 | -H |
55 | -C(O)CH2CH2- | 2,3-二氯苯基 | -CH3 | -H |
56 | -C(O)CH2CH2- | 3,4-二氯苯基 | -CH3 | -H |
57 | -C(O)CH2CH2- | 3,5-二氯苯基 | -CH3 | -H |
58 | -C(O)CH2CH2- | 2-羟基苯基 | -CH3 | -H |
59 | -C(O)CH2CH2- | 3-羟基苯基 | -CH3 | -H |
60 | -C(O)CH2CH2- | 4-羟基苯基 | -CH3 | -H |
61 | -C(O)CH2CH2- | 2-甲氧基苯基 | -CH3 | -H |
62 | -C(O)CH2CH2- | 3-甲氧基苯基 | -CH3 | -H |
63 | -C(O)CH2CH2- | 4-甲氧基苯基 | -CH3 | -H |
64 | -C(O)CH2CH2- | 2,3-二甲氧基苯基 | -CH3 | -H |
65 | -C(O)CH2CH2- | 3,4-二甲氧基苯基 | -CH3 | -H |
66 | -C(O)CH2CH2- | 3,5-二甲氧基苯基 | -CH3 | -H |
67 | -C(O)CH2CH2- | 苯基 | -CH2CH3 | -H |
68 | -C(O)CH2CH2- | 2-氟苯基 | -CH2CH3 | -H |
69 | -C(O)CH2CH2- | 3-氟苯基 | -CH2CH3 | -H |
70 | -C(O)CH2CH2- | 4-氟苯基 | -CH2CH3 | -H |
71 | -C(O)CH2CH2- | 2,3-二氟苯基 | -CH2CH3 | -H |
72 | -C(O)CH2CH2- | 3,4-二氟苯基 | -CH2CH3 | -H |
73 | -C(O)CH2CH2- | 3,5-二氟苯基 | -CH2CH3 | -H |
74 | -C(O)CH2CH2- | 2-氯苯基 | -CH2CH3 | -H |
75 | -C(O)CH2CH2- | 3-氯苯基 | -CH2CH3 | -H |
76 | -C(O)CH2CH2- | 4-氯苯基 | -CH2CH3 | -H |
77 | -C(O)CH2CH2- | 2,3-二氯苯基 | -CH2CH3 | -H |
78 | -C(O)CH2CH2- | 3,4-二氯苯基 | -CH2CH3 | -H |
79 | -C(O)CH2CH2- | 3,5-二氯苯基 | -CH2CH3 | -H |
80 | -C(O)CH2CH2- | 2-羟基苯基 | -CH2CH3 | -H |
81 | -C(O)CH2CH2- | 3-羟基苯基 | -CH2CH3 | -H |
82 | -C(O)CH2CH2- | 4-羟基苯基 | -CH2CH3 | -H |
83 | -C(O)CH2CH2- | 2-甲氧基苯基 | -CH2CH3 | -H |
84 | -C(O)CH2CH2- | 3-甲氧基苯基 | -CH2CH3 | -H |
85 | -C(O)CH2CH2- | 4-甲氧基苯基 | -CH2CH3 | -H |
86 | -C(O)CH2CH2- | 2,3-二甲氧基苯基 | -CH2CH3 | -H |
87 | -C(O)CH2CH2- | 3,4-二甲氧基苯基 | -CH2CH3 | -H |
88 | -C(O)CH2CH2- | 3,5-二甲氧基苯基 | -CH2CH3 | -H |
序号 | L | R1 | R4 |
89 | -C(O)CH2- | 苯基 | 甲基 |
90 | -C(O)CH2- | 苯基 | 乙基 |
91 | -C(O)CH2- | 苯基 | 苯基 |
92 | -C(O)CH2- | 苯基 | 噻吩-2-基 |
93 | -C(O)CH2- | 苯基 | 噻唑-2-基 |
94 | -C(O)CH2- | 苯基 | 噁唑-2-基 |
95 | -C(O)CH2- | 苯基 | 异噁唑-3-基 |
96 | -C(O)CH2- | 3-氯苯基 | 甲基 |
97 | -C(O)CH2- | 3-氯苯基 | 乙基 |
98 | -C(O)CH2- | 3-氯苯基 | 苯基 |
99 | -C(O)CH2- | 3-氯苯基 | 噻吩-2-基 |
100 | -C(O)CH2- | 3-氯苯基 | 噻唑-2-基 |
101 | -C(O)CH2- | 3-氯苯基 | 噁唑-2-基 |
102 | -C(O)CH2- | 3-氯苯基 | 异噁唑-3-基 |
103 | -C(O)CH2- | 3-甲氧基苯基 | 甲基 |
104 | -C(O)CH2- | 3-甲氧基苯基 | 乙基 |
105 | -C(O)CH2- | 3-甲氧基苯基 | 苯基 |
106 | -C(O)CH2- | 3-甲氧基苯基 | 噻吩-2-基 |
107 | -C(O)CH2- | 3-甲氧基苯基 | 噻唑-2-基 |
108 | -C(O)CH2- | 3-甲氧基苯基 | 噁唑-2-基 |
109 | -C(O)CH2- | 3-甲氧基苯基 | 异噁唑-3-基 |
110 | -C(O)CH2- | 3-氟苯基 | 甲基 |
111 | -C(O)CH2- | 3-氟苯基 | 乙基 |
112 | -C(O)CH2- | 3-氟苯基 | 苯基 |
113 | -C(O)CH2- | 3-氟苯基 | 噻吩-2-基 |
114 | -C(O)CH2- | 3-氟苯基 | 噻唑-2-基 |
115 | -C(O)CH2- | 3-氟苯基 | 噁唑-2-基 |
116 | -C(O)CH2- | 3-氟苯基 | 异噁唑-3-基 |
117 | -C(O)CH2- | 2,5-二甲基噻唑-4-基 | 甲基 |
118 | -C(O)CH2- | 2,5-二甲基噻唑-4-基 | 乙基 |
119 | -C(O)CH2- | 2,5-二甲基噻唑-4-基 | 苯基 |
120 | -C(O)CH2- | 2,5-二甲基噻唑-4-基 | 噻吩-2-基 |
121 | -C(O)CH2- | 2,5-二甲基噻唑-4-基 | 噻唑-2-基 |
122 | -C(O)CH2- | 2,5-二甲基噻唑-4-基 | 噁唑-2-基 |
123 | -C(O)CH2- | 2,5-二甲基噻唑-4-基 | 异噁唑-3-基 |
124 | -C(O)CH2- | 2,4-二甲基噻唑-5-基 | 甲基 |
125 | -C(O)CH2- | 2,4-二甲基噻唑-5-基 | 乙基 |
126 | -C(O)CH2- | 2,4-二甲基噻唑-5-基 | 苯基 |
127 | -C(O)CH2- | 2,4-二甲基噻唑-5-基 | 噻吩-2-基 |
128 | -C(O)CH2- | 2,4-二甲基噻唑-5-基 | 噻唑-2-基 |
129 | -C(O)CH2- | 2,4-二甲基噻唑-5-基 | 噁唑-2-基 |
130 | -C(O)CH2- | 2,4-二甲基噻唑-5-基 | 异噁唑-3-基 |
131 | -C(O)CH2- | 4-乙基噻唑-2-基 | 甲基 |
132 | -C(O)CH2- | 4-乙基噻唑-2-基 | 乙基 |
133 | -C(O)CH2- | 4-乙基噻唑-2-基 | 苯基 |
134 | -C(O)CH2- | 4-乙基噻唑-2-基 | 噻吩-2-基 |
135 | -C(O)CH2- | 4-乙基噻唑-2-基 | 噻唑-2-基 |
136 | -C(O)CH2- | 4-乙基噻唑-2-基 | 噁唑-2-基 |
137 | -C(O)CH2- | 4-乙基噻唑-2-基 | 异噁唑-3-基 |
138 | -C(O)CH2- | 3-甲基-1,2,4-噁二唑-5-基 | 甲基 |
139 | -C(O)CH2- | 3-甲基-1,2,4-噁二唑-5-基 | 乙基 |
140 | -C(O)CH2- | 3-甲基-1,2,4-噁二唑-5-基 | 苯基 |
141 | -C(O)CH2- | 3-甲基-1,2,4-噁二唑-5-基 | 噻吩-2-基 |
142 | -C(O)CH2- | 3-甲基-1,2,4-噁二唑-5-基 | 噻唑-2-基 |
143 | -C(O)CH2- | 3-甲基-1,2,4-噁二唑-5-基 | 噁唑-2-基 |
144 | -C(O)CH2- | 3-甲基-1,2,4-噁二唑-5-基 | 异噁唑-3-基 |
145 | -C(O)CH2CH2- | 苯基 | 甲基 |
146 | -C(O)CH2CH2- | 苯基 | 乙基 |
147 | -C(O)CH2CH2- | 苯基 | 苯基 |
148 | -C(O)CH2CH2- | 苯基 | 噻吩-2-基 |
149 | -C(O)CH2CH2- | 苯基 | 噻唑-2-基 |
150 | -C(O)CH2CH2- | 苯基 | 噁唑-2-基 |
151 | -C(O)CH2CH2- | 苯基 | 异噁唑-3-基 |
152 | -C(O)CH2CH2- | 3-氯苯基 | 甲基 |
153 | -C(O)CH2CH2- | 3-氯苯基 | 乙基 |
154 | -C(O)CH2CH2- | 3-氯苯基 | 苯基 |
155 | -C(O)CH2CH2- | 3-氯苯基 | 噻吩-2-基 |
156 | -C(O)CH2CH2- | 3-氯苯基 | 噻唑-2-基 |
157 | -C(O)CH2CH2- | 3-氯苯基 | 噁唑-2-基 |
158 | -C(O)CH2CH2- | 3-氯苯基 | 异噁唑-3-基 |
159 | -C(O)CH2CH2- | 3-甲氧基苯基 | 甲基 |
160 | -C(O)CH2CH2- | 3-甲氧基苯基 | 乙基 |
161 | -C(O)CH2CH2- | 3-甲氧基苯基 | 苯基 |
162 | -C(O)CH2CH2- | 3-甲氧基苯基 | 噻吩-2-基 |
163 | -C(O)CH2CH2- | 3-甲氧基苯基 | 噻唑-2-基 |
164 | -C(O)CH2CH2- | 3-甲氧基苯基 | 噁唑-2-基 |
165 | -C(O)CH2CH2- | 3-甲氧基苯基 | 异噁唑-3-基 |
166 | -C(O)CH2CH2- | 3-氟苯基 | 甲基 |
167 | -C(O)CH2CH2- | 3-氟苯基 | 乙基 |
168 | -C(O)CH2CH2- | 3-氟苯基 | 苯基 |
169 | -C(O)CH2CH2- | 3-氟苯基 | 噻吩-2-基 |
170 | -C(O)CH2CH2- | 3-氟苯基 | 噻唑-2-基 |
171 | -C(O)CH2CH2- | 3-氟苯基 | 噁唑-2-基 |
172 | -C(O)CH2CH2- | 3-氟苯基 | 异噁唑-3-基 |
173 | -C(O)CH2CH2- | 2,5-二甲基噻唑-4-基 | 甲基 |
174 | -C(O)CH2CH2- | 2,5-二甲基噻唑-4-基 | 乙基 |
175 | -C(O)CH2CH2- | 2,5-二甲基噻唑-4-基 | 苯基 |
176 | -C(O)CH2CH2- | 2,5-二甲基噻唑-4-基 | 噻吩-2-基 |
177 | -C(O)CH2CH2- | 2,5-二甲基噻唑-4-基 | 噻唑-2-基 |
178 | -C(O)CH2CH2- | 2,5-二甲基噻唑-4-基 | 噁唑-2-基 |
179 | -C(O)CH2CH2- | 2,5-二甲基噻唑-4-基 | 异噁唑-3-基 |
180 | -C(O)CH2CH2- | 2,4-二甲基噻唑-5-基 | 甲基 |
181 | -C(O)CH2CH2- | 2,4-二甲基噻唑-5-基 | 乙基 |
182 | -C(O)CH2CH2- | 2,4-二甲基噻唑-5-基 | 苯基 |
183 | -C(O)CH2CH2- | 2,4-二甲基噻唑-5-基 | 噻吩-2-基 |
184 | -C(O)CH2CH2- | 2,4-二甲基噻唑-5-基 | 噻唑-2-基 |
185 | -C(O)CH2CH2- | 2,4-二甲基噻唑-5-基 | 噁唑-2-基 |
186 | -C(O)CH2CH2- | 2,4-二甲基噻唑-5-基 | 异噁唑-3-基 |
187 | -C(O)CH2CH2- | 4-乙基噻唑-2-基 | 甲基 |
188 | -C(O)CH2CH2- | 4-乙基噻唑-2-基 | 乙基 |
189 | -C(O)CH2CH2- | 4-乙基噻唑-2-基 | 苯基 |
190 | -C(O)CH2CH2- | 4-乙基噻唑-2-基 | 噻吩-2-基 |
191 | -C(O)CH2CH2- | 4-乙基噻唑-2-基 | 噻唑-2-基 |
192 | -C(O)CH2CH2- | 4-乙基噻唑-2-基 | 噁唑-2-基 |
193 | -C(O)CH2CH2- | 4-乙基噻唑-2-基 | 异噁唑-3-基 |
194 | -C(O)CH2CH2- | 3-甲基-1,2,4-噁二唑-5-基 | 甲基 |
195 | -C(O)CH2CH2- | 3-甲基-1,2,4-噁二唑-5-基 | 乙基 |
196 | -C(O)CH2CH2- | 3-甲基-1,2,4-噁二唑-5-基 | 苯基 |
197 | -C(O)CH2CH2- | 3-甲基-1,2,4-噁二唑-5-基 | 噻吩-2-基 |
198 | -C(O)CH2CH2- | 3-甲基-1,2,4-噁二唑-5-基 | 噻唑-2-基 |
199 | -C(O)CH2CH2- | 3-甲基-1,2,4-噁二唑-5-基 | 噁唑-2-基 |
200 | -C(O)CH2CH2- | 3-甲基-1,2,4-噁二唑-5-基 | 异噁唑-3-基 |
序号 | R2 | R3 | R6a |
201 | 甲基 | 氢 | 苯基 |
202 | 甲基 | 氢 | 2-氟苯基 |
203 | 甲基 | 氢 | 3-氟苯基 |
204 | 甲基 | 氢 | 4-氟苯基 |
205 | 甲基 | 氢 | 3,4-二氟苯基 |
206 | 甲基 | 氢 | 2-氯苯基 |
207 | 甲基 | 氢 | 3-氯苯基 |
208 | 甲基 | 氢 | 4-氯苯基 |
209 | 甲基 | 氢 | 3,4-二氯苯基 |
210 | 甲基 | 氢 | 2-甲氧基苯基 |
211 | 甲基 | 氢 | 3-甲氧基苯基 |
212 | 甲基 | 氢 | 4-甲氧基苯基 |
213 | 乙基 | 氢 | 苯基 |
214 | 乙基 | 氢 | 2-氟苯基 |
215 | 乙基 | 氢 | 3-氟苯基 |
216 | 乙基 | 氢 | 4-氟苯基 |
217 | 乙基 | 氢 | 3,4-二氟苯基 |
218 | 乙基 | 氢 | 2-氯苯基 |
219 | 乙基 | 氢 | 3-氯苯基 |
220 | 乙基 | 氢 | 4-氯苯基 |
221 | 乙基 | 氢 | 3,4-二氯苯基 |
222 | 乙基 | 氢 | 2-甲氧基苯基 |
223 | 乙基 | 氢 | 3-甲氧基苯基 |
224 | 乙基 | 氢 | 4-甲氧基苯基 |
序号 | R2 | R3 | R6a |
225 | 甲基 | 氢 | 3-甲基-1,2,4-噁二唑-5-基 |
226 | 甲基 | 氢 | 噻吩-2-基 |
227 | 甲基 | 氢 | 噻唑-2-基 |
228 | 甲基 | 氢 | 噁唑-2-基 |
229 | 甲基 | 氢 | 异噁唑-3-基 |
230 | 乙基 | 氢 | 3-甲基-1,2,4-噁二唑-5-基 |
231 | 乙基 | 氢 | 噻吩-2-基 |
232 | 乙基 | 氢 | 噻唑-2-基 |
233 | 乙基 | 氢 | 噁唑-2-基 |
234 | 乙基 | 氢 | 异噁唑-3-基 |
235 | 乙基 | 甲基 | 3-甲基-1,2,4-噁二唑-5-基 |
236 | 乙基 | 甲基 | 噻吩-2-基 |
237 | 乙基 | 甲基 | 噻唑-2-基 |
238 | 乙基 | 甲基 | 噁唑-2-基 |
239 | 乙基 | 甲基 | 异噁唑-3-基 |
240 | 噻吩-2-基 | 氢 | 3-甲基-1,2,4-噁二唑-5-基 |
241 | 噻吩-2-基 | 氢 | 噻吩-2-基 |
242 | 噻吩-2-基 | 氢 | 噻唑-2-基 |
243 | 噻吩-2-基 | 氢 | 噁唑-2-基 |
244 | 噻吩-2-基 | 氢 | 异噁唑-3-基 |
245 | 异噁唑-3-基 | 氢 | 3-甲基-1,2,4-噁二唑-5-基 |
246 | 异噁唑-3-基 | 氢 | 噻吩-2-基 |
247 | 异噁唑-3-基 | 氢 | 噻唑-2-基 |
248 | 异噁唑-3-基 | 氢 | 噁唑-2-基 |
249 | 异噁唑-3-基 | 氢 | 异噁唑-3-基 |
序号 | R2 | R3 | R1 |
250 | 乙基 | 氢 | 噻吩-2-基 |
251 | 乙基 | 氢 | 噻唑-2-基 |
252 | 乙基 | 氢 | 噁唑-2-基 |
253 | 乙基 | 氢 | 异噁唑-3-基 |
254 | 乙基 | 氢 | 噻吩-2-基 |
255 | 乙基 | 氢 | 噻唑-2-基 |
256 | 乙基 | 氢 | 噁唑-2-基 |
257 | 乙基 | 氢 | 异噁唑-3-基 |
258 | 乙基 | 氢 | 噻吩-2-基 |
259 | 乙基 | 氢 | 噻唑-2-基 |
260 | 乙基 | 甲基 | 甲基 |
261 | 乙基 | 甲基 | 乙基 |
262 | 乙基 | 甲基 | 丙基 |
263 | 乙基 | 甲基 | 异丙基 |
264 | 乙基 | 甲基 | 丁基 |
265 | 乙基 | 甲基 | 苯基 |
266 | 乙基 | 甲基 | 苄基 |
267 | 乙基 | 甲基 | 2-氟苯基 |
268 | 乙基 | 甲基 | 3-氟苯基 |
269 | 乙基 | 甲基 | 4-氟苯基 |
270 | 苯基 | 氢 | 甲基 |
271 | 苯基 | 氢 | 乙基 |
272 | 苯基 | 氢 | 丙基 |
273 | 苯基 | 氢 | 异丙基 |
274 | 苯基 | 氢 | 丁基 |
275 | 苯基 | 氢 | 苯基 |
276 | 苯基 | 氢 | 苄基 |
277 | 苯基 | 氢 | 2-氟苯基 |
278 | 苯基 | 氢 | 3-氟苯基 |
279 | 苯基 | 氢 | 4-氟苯基 |
280 | 噻吩-2-基 | 氢 | 甲基 |
281 | 噻吩-2-基 | 氢 | 乙基 |
282 | 噻吩-2-基 | 氢 | 丙基 |
283 | 噻吩-2-基 | 氢 | 异丙基 |
284 | 噻吩-2-基 | 氢 | 丁基 |
285 | 噻吩-2-基 | 氢 | 苯基 |
286 | 噻吩-2-基 | 氢 | 苄基 |
287 | 噻吩-2-基 | 氢 | 2-氟苯基 |
288 | 噻吩-2-基 | 氢 | 3-氟苯基 |
289 | 噻吩-2-基 | 氢 | 4-氟苯基 |
序号 | R2 | R3 | R1 |
290 | 甲基 | 氢 | 苯基 |
291 | 甲基 | 氢 | 苄基 |
292 | 甲基 | 氢 | 2-氟苯基 |
293 | 甲基 | 氢 | 3-氟苯基 |
294 | 甲基 | 氢 | 4-氟苯基 |
295 | 甲基 | 氢 | 2-氯苯基 |
296 | 甲基 | 氢 | 3-氯苯基 |
297 | 甲基 | 氢 | 4-氯苯基 |
298 | 乙基 | 氢 | 苯基 |
299 | 乙基 | 氢 | 苄基 |
300 | 乙基 | 氢 | 2-氟苯基 |
301 | 乙基 | 氢 | 3-氟苯基 |
302 | 乙基 | 氢 | 4-氟苯基 |
303 | 乙基 | 氢 | 2-氯苯基 |
304 | 乙基 | 氢 | 3-氯苯基 |
305 | 乙基 | 氢 | 4-氯苯基 |
306 | 噻吩-2-基 | 氢 | 苯基 |
307 | 噻吩-2-基 | 氢 | 苄基 |
308 | 噻吩-2-基 | 氢 | 2-氟苯基 |
309 | 噻吩-2-基 | 氢 | 3-氟苯基 |
310 | 噻吩-2-基 | 氢 | 4-氟苯基 |
311 | 噻吩-2-基 | 氢 | 2-氯苯基 |
312 | 噻吩-2-基 | 氢 | 3-氯苯基 |
313 | 噻吩-2-基 | 氢 | 4-氯苯基 |
序号 | R1 | R4 |
314 | 甲基 | 甲基 |
315 | 乙基 | 甲基 |
316 | 正丙基 | 甲基 |
317 | 异丙基 | 甲基 |
318 | 苯基 | 甲基 |
319 | 苄基 | 甲基 |
320 | 2-氟苯基 | 甲基 |
321 | 2-氯苯基 | 甲基 |
322 | 噻吩-2-基 | 甲基 |
323 | 噻唑-2-基 | 甲基 |
324 | 噁唑-2-基 | 甲基 |
325 | 异噁唑-3-基 | 甲基 |
326 | 甲基 | 乙基 |
327 | 乙基 | 乙基 |
328 | 正丙基 | 乙基 |
329 | 异丙基 | 乙基 |
330 | 苯基 | 乙基 |
331 | 苄基 | 乙基 |
332 | 2-氟苯基 | 乙基 |
333 | 2-氯苯基 | 乙基 |
334 | 噻吩-2-基 | 乙基 |
335 | 噻唑-2-基 | 乙基 |
336 | 噁唑-2-基 | 乙基 |
337 | 异噁唑-3-基 | 乙基 |
338 | 甲基 | 噻吩-2-基 |
339 | 乙基 | 噻吩-2-基 |
340 | 正丙基 | 噻吩-2-基 |
341 | 异丙基 | 噻吩-2-基 |
342 | 苯基 | 噻吩-2-基 |
343 | 苄基 | 噻吩-2-基 |
344 | 2-氟苯基 | 噻吩-2-基 |
345 | 2-氯苯基 | 噻吩-2-基 |
346 | 噻吩-2-基 | 噻吩-2-基 |
347 | 噻唑-2-基 | 噻吩-2-基 |
348 | 噁唑-2-基 | 噻吩-2-基 |
349 | 异噁唑-3-基 | 噻吩-2-基 |
350 | 甲基 | 噻唑-2-基 |
351 | 乙基 | 噻唑-2-基 |
352 | 正丙基 | 噻唑-2-基 |
353 | 异丙基 | 噻唑-2-基 |
354 | 苯基 | 噻唑-2-基 |
355 | 苄基 | 噻唑-2-基 |
356 | 2-氟苯基 | 噻唑-2-基 |
357 | 2-氯苯基 | 噻唑-2-基 |
358 | 噻吩-2-基 | 噻唑-2-基 |
359 | 噻唑-2-基 | 噻唑-2-基 |
360 | 噁唑-2-基 | 噻唑-2-基 |
361 | 异噁唑-3-基 | 噻唑-2-基 |
362 | 甲基 | 噁唑-2-基 |
363 | 乙基 | 噁唑-2-基 |
364 | 正丙基 | 噁唑-2-基 |
365 | 异丙基 | 噁唑-2-基 |
366 | 苯基 | 噁唑-2-基 |
367 | 苄基 | 噁唑-2-基 |
368 | 2-氟苯基 | 噁唑-2-基 |
369 | 2-氯苯基 | 噁唑-2-基 |
370 | 噻吩-2-基 | 噁唑-2-基 |
371 | 噻唑-2-基 | 噁唑-2-基 |
372 | 噁唑-2-基 | 噁唑-2-基 |
373 | 异噁唑-3-基 | 噁唑-2-基 |
序号 | R4 | L | R1 |
374 | 甲基 | -SO2- | 甲基 |
375 | 乙基 | -SO2- | 甲基 |
376 | 苯基 | -SO2- | 甲基 |
377 | 噻吩-2-基 | -SO2- | 甲基 |
378 | 甲基 | -SO2- | 三氟甲基 |
379 | 乙基 | -SO2- | 三氟甲基 |
380 | 苯基 | -SO2- | 三氟甲基 |
381 | 噻吩-2-基 | -SO2- | 三氟甲基 |
382 | 甲基 | -SO2- | 乙基 |
383 | 乙基 | -SO2- | 乙基 |
384 | 苯基 | -SO2- | 乙基 |
385 | 噻吩-2-基 | -SO2- | 乙基 |
386 | 甲基 | -SO2- | 2,2,2-三氟乙基 |
387 | 乙基 | -SO2- | 2,2,2-三氟乙基 |
388 | 苯基 | -SO2- | 2,2,2-三氟乙基 |
389 | 噻吩-2-基 | -SO2- | 2,2,2-三氟乙基 |
390 | 甲基 | -SO2- | 苯基 |
391 | 乙基 | -SO2- | 苯基 |
392 | 苯基 | -SO2- | 苯基 |
393 | 噻吩-2-基 | -SO2- | 苯基 |
394 | 甲基 | -SO2- | 4-氟苯基 |
395 | 乙基 | -SO2- | 4-氟苯基 |
396 | 苯基 | -SO2- | 4-氟苯基 |
397 | 噻吩-2-基 | -SO2- | 4-氟苯基 |
398 | 甲基 | -SO2- | 3,4-二氢-2H-苯并[b][1,4]噁嗪-7-基 |
399 | 乙基 | -SO2- | 3,4-二氢-2H-苯并[b][1,4]噁嗪-7-基 |
400 | 苯基 | -SO2- | 3,4-二氢-2H-苯并[b][1,4]噁嗪-7-基 |
401 | 噻吩-2-基 | -SO2- | 3,4-二氢-2H-苯并[b][1,4]噁嗪-7-基 |
402 | 甲基 | -SO2- | 1-甲基-1H-咪唑-4-基 |
403 | 乙基 | -SO2- | 1-甲基-1H-咪唑-4-基 |
404 | 苯基 | -SO2- | 1-甲基-1H-咪唑-4-基 |
405 | 噻吩-2-基 | -SO2- | 1-甲基-1H-咪唑-4-基 |
406 | 甲基 | -SO2- | 4-乙酰胺基苯基 |
407 | 乙基 | -SO2- | 4-乙酰胺基苯基 |
408 | 苯基 | -SO2- | 4-乙酰胺基苯基 |
409 | 噻吩-2-基 | -SO2- | 4-乙酰胺基苯基 |
410 | 甲基 | -SO2CH2- | 苯基 |
411 | 乙基 | -SO2CH2- | 苯基 |
412 | 苯基 | -SO2CH2- | 苯基 |
413 | 噻吩-2-基 | -SO2CH2- | 苯基 |
414 | 甲基 | -SO2CH2- | (4-甲基羧基苯基)甲基 |
415 | 乙基 | -SO2CH2- | (4-甲基羧基苯基)甲基 |
416 | 苯基 | -SO2CH2- | (4-甲基羧基苯基)甲基 |
417 | 噻吩-2-基 | -SO2CH2- | (4-甲基羧基苯基)甲基 |
418 | 甲基 | -SO2CH2- | (2-甲基噻唑-4-基)甲基 |
419 | 乙基 | -SO2CH2- | (2-甲基噻唑-4-基)甲基 |
420 | 苯基 | -SO2CH2- | (2-甲基噻唑-4-基)甲基 |
421 | 噻吩-2-基 | -SO2CH2- | (2-甲基噻唑-4-基)甲基 |
422 | 甲基 | -SO2CH2CH2- | 苯基 |
423 | 乙基 | -SO2CH2CH2- | 苯基 |
424 | 苯基 | -SO2CH2CH2- | 苯基 |
425 | 噻吩-2-基 | -SO2CH2CH2- | 苯基 |
序号 | R4 | R1 |
426 | -CH3 | 4-(甲氧基羰基)噻唑-5-基 |
427 | -CH3 | 4-[(2-甲氧基-2-氧乙基)氨基甲酰基]噻唑-5-基 |
428 | -CH3 | 5-[1-N-(2-甲氧基-2-氧乙基)-1-H-吲哚-3-基]噁唑-2-基 |
429 | -CH3 | 5-(2-甲氧基苯基)噁唑-2-基 |
430 | -CH3 | 5-[(S)-1-(叔丁氧基羰基)-2-苯基乙基]噁唑-2-基 |
431 | -CH3 | 5-[4-(甲基羧基)苯基]噁唑-2-基 |
432 | -CH3 | 5-(3-甲氧基苄基)噁唑-2-基 |
433 | -CH3 | 5-(4-苯基)噁唑-2-基 |
434 | -CH3 | 5-(2-甲氧基苯基)噻唑-2-基 |
435 | -CH3 | 5-(3-甲氧基苯基)噻唑-2-基 |
436 | -CH3 | 5-(4-氟苯基)噻唑-2-基 |
437 | -CH3 | 5-(2,4-二氟苯基)噻唑-2-基 |
438 | -CH3 | 5-(3-甲氧基苄基)噻唑-2-基 |
439 | -CH3 | 4-(3-甲氧基苯基)噻唑-2-基 |
440 | -CH3 | 4-(4-氟苯基)噻唑-2-基 |
441 | -CH2CH3 | 4-(甲氧基羰基)噻唑-5-基 |
442 | -CH2CH3 | 4-[(2-甲氧基-2-氧乙基)氨基甲酰基]噻唑-5-基 |
443 | -CH2CH3 | 5-[1-N-(2-甲氧基-2-氧乙基)-1-H-吲哚-3-基]噁唑-2-基 |
444 | -CH2CH3 | 5-(2-甲氧基苯基)噁唑-2-基 |
445 | -CH2CH3 | 5-[(S)-1-(叔丁氧基羰基)-2-苯基乙基]噁唑-2-基 |
446 | -CH2CH3 | 5-[4-(甲基羧基)苯基]噁唑-2-基 |
447 | -CH2CH3 | 5-(3-甲氧基苄基)噁唑-2-基 |
448 | -CH2CH3 | 5-(4-苯基)噁唑-2-基 |
449 | -CH2CH3 | 5-(2-甲氧基苯基)噻唑-2-基 |
450 | -CH2CH3 | 5-(3-甲氧基苯基)噻唑-2-基 |
451 | -CH2CH3 | 5-(4-氟苯基)噻唑-2-基 |
452 | -CH2CH3 | 5-(2,4-二氟苯基)噻唑-2-基 |
453 | -CH2CH3 | 5-(3-甲氧基苄基)噻唑-2-基 |
454 | -CH2CH3 | 4-(3-甲氧基苯基)噻唑-2-基 |
455 | -CH2CH3 | 4-(4-氟苯基)噻唑-2-基 |
456 | 环丙基 | 4-(甲氧基羰基)噻唑-5-基 |
457 | 环丙基 | 4-[(2-甲氧基-2-氧乙基)氨基甲酰基]噻唑-5-基 |
458 | 环丙基 | 5-[1-N-(2-甲氧基-2-氧乙基)-1-H-吲哚-3-基]噁唑-2-基 |
459 | 环丙基 | 5-(2-甲氧基苯基)噁唑-2-基 |
460 | 环丙基 | 5-[(S)-1-(叔丁氧基羰基)-2-苯基乙基]噁唑-2-基 |
461 | 环丙基 | 5-[4-(甲基羧基)苯基]噁唑-2-基 |
462 | 环丙基 | 5-(3-甲氧基苄基)噁唑-2-基 |
463 | 环丙基 | 5-(4-苯基)噁唑-2-基 |
464 | 环丙基 | 5-(2-甲氧基苯基)噻唑-2-基 |
465 | 环丙基 | 5-(3-甲氧基苯基)噻唑-2-基 |
466 | 环丙基 | 5-(4-氟苯基)噻唑-2-基 |
467 | 环丙基 | 5-(2,4-二氟苯基)噻唑-2-基 |
468 | 环丙基 | 5-(3-甲氧基苄基)噻唑-2-基 |
469 | 环丙基 | 4-(3-甲氧基苯基)噻唑-2-基 |
470 | 环丙基 | 4-(4-氟苯基)噻唑-2-基 |
序号 | R4 | R1 |
471 | 苯基 | 4-(甲氧基羰基)噻唑-5-基 |
472 | 苯基 | 4-[(2-甲氧基-2-氧乙基)氨基甲酰基]噻唑-5-基 |
473 | 苯基 | 5-[1-N-(2-甲氧基-2-氧乙基)-1-H-吲哚-3-基]噁唑-2-基 |
474 | 苯基 | 5-(2-甲氧基苯基)噁唑-2-基 |
475 | 苯基 | 5-[(S)-1-(叔丁氧基羰基)-2-苯基乙基]噁唑-2-基 |
476 | 苯基 | 5-[4-(甲基羧基)苯基]噁唑-2-基 |
477 | 苯基 | 5-(3-甲氧基苄基)噁唑-2-基 |
478 | 苯基 | 5-(4-苯基)噁唑-2-基 |
479 | 苯基 | 5-(2-甲氧基苯基)噻唑-2-基 |
480 | 苯基 | 5-(3-甲氧基苯基)噻唑-2-基 |
481 | 苯基 | 5-(4-氟苯基)噻唑-2-基 |
482 | 苯基 | 5-(2,4-二氟苯基)噻唑-2-基 |
483 | 苯基 | 5-(3-甲氧基苄基)噻唑-2-基 |
484 | 苯基 | 4-(3-甲氧基苯基)噻唑-2-基 |
485 | 苯基 | 4-(4-氟苯基)噻唑-2-基 |
486 | 噻吩-2-基 | 4-(甲氧基羰基)噻唑-5-基 |
487 | 噻吩-2-基 | 4-[(2-甲氧基-2-氧乙基)氨基甲酰基]噻唑-5-基 |
488 | 噻吩-2-基 | 5-[1-N-(2-甲氧基-2-氧乙基)-1-H-吲哚-3-基]噁唑-2-基 |
489 | 噻吩-2-基 | 5-(2-甲氧基苯基)噁唑-2-基 |
490 | 噻吩-2-基 | 5-[(S)-1-(叔丁氧基羰基)-2-苯基乙基]噁唑-2-基 |
491 | 噻吩-2-基 | 5-[4-(甲基羧基)苯基]噁唑-2-基 |
492 | 噻吩-2-基 | 5-(3-甲氧基苄基)噁唑-2-基 |
493 | 噻吩-2-基 | 5-(4-苯基)噁唑-2-基 |
494 | 噻吩-2-基 | 5-(2-甲氧基苯基)噻唑-2-基 |
495 | 噻吩-2-基 | 5-(3-甲氧基苯基)噻唑-2-基 |
496 | 噻吩-2-基 | 5-(4-氟苯基)噻唑-2-基 |
497 | 噻吩-2-基 | 5-(2,4-二氟苯基)噻唑-2-基 |
498 | 噻吩-2-基 | 5-(3-甲氧基苄基)噻唑-2-基 |
499 | 噻吩-2-基 | 4-(3-甲氧基苯基)噻唑-2-基 |
500 | 噻吩-2-基 | 4-(4-氟苯基)噻唑-2-基 |
501 | 环丙基 | 4-(甲氧基羰基)噻唑-5-基 |
502 | 环丙基 | 4-[(2-甲氧基-2-氧乙基)氨基甲酰基]噻唑-5-基 |
503 | 环丙基 | 5-[1-N-(2-甲氧基-2-氧乙基)-1-H-吲哚-3-基]噁唑-2-基 |
504 | 环丙基 | 5-(2-甲氧基苯基)噁唑-2-基 |
505 | 环丙基 | 5-[(S)-1-(叔丁氧基羰基)-2-苯基乙基]噁唑-2-基 |
506 | 环丙基 | 5-[4-(甲基羧基)苯基]噁唑-2-基 |
507 | 环丙基 | 5-(3-甲氧基苄基)噁唑-2-基 |
508 | 环丙基 | 5-(4-苯基)噁唑-2-基 |
509 | 环丙基 | 5-(2-甲氧基苯基)噻唑-2-基 |
510 | 环丙基 | 5-(3-甲氧基苯基)噻唑-2-基 |
511 | 环丙基 | 5-(4-氟苯基)噻唑-2-基 |
512 | 环丙基 | 5-(2,4-二氟苯基)噻唑-2-基 |
513 | 环丙基 | 5-(3-甲氧基苄基)噻唑-2-基 |
514 | 环丙基 | 4-(3-甲氧基苯基)噻唑-2-基 |
515 | 环丙基 | 4-(4-氟苯基)噻唑-2-基 |
序号 | R4 | R1 |
516 | 苯基 | 4-(甲氧基羰基)噻唑-5-基 |
517 | 苯基 | 4-[(2-甲氧基-2-氧乙基)氨基甲酰基]噻唑-5-基 |
518 | 苯基 | 5-[1-N-(2-甲氧基-2-氧乙基)-1-H-吲哚-3-基]噁唑-2-基 |
519 | 苯基 | 5-(2-甲氧基苯基)噁唑-2-基 |
520 | 苯基 | 5-[(S)-1-(叔丁氧基羰基)-2-苯基乙基]噁唑-2-基 |
521 | 苯基 | 5-[4-(甲基羧基)苯基]噁唑-2-基 |
522 | 苯基 | 5-(3-甲氧基苄基)噁唑-2-基 |
523 | 苯基 | 5-(4-苯基)噁唑-2-基 |
524 | 苯基 | 5-(2-甲氧基苯基)噻唑-2-基 |
525 | 苯基 | 5-(3-甲氧基苯基)噻唑-2-基 |
526 | 苯基 | 5-(4-氟苯基)噻唑-2-基 |
527 | 苯基 | 5-(2,4-二氟苯基)噻唑-2-基 |
528 | 苯基 | 5-(3-甲氧基苄基)噻唑-2-基 |
529 | 苯基 | 4-(3-甲氧基苯基)噻唑-2-基 |
530 | 苯基 | 4-(4-氟苯基)噻唑-2-基 |
531 | 噻吩-2-基 | 4-(甲氧基羰基)噻唑-5-基 |
532 | 噻吩-2-基 | 4-[(2-甲氧基-2-氧乙基)氨基甲酰基]噻唑-5-基 |
533 | 噻吩-2-基 | 5-[1-N-(2-甲氧基-2-氧乙基)-1-H-吲哚-3-基]噁唑-2-基 |
534 | 噻吩-2-基 | 5-(2-甲氧基苯基)噁唑-2-基 |
535 | 噻吩-2-基 | 5-[(S)-1-(叔丁氧基羰基)-2-苯基乙基]噁唑-2-基 |
536 | 噻吩-2-基 | 5-[4-(甲基羧基)苯基]噁唑-2-基 |
537 | 噻吩-2-基 | 5-(3-甲氧基苄基)噁唑-2-基 |
538 | 噻吩-2-基 | 5-(4-苯基)噁唑-2-基 |
539 | 噻吩-2-基 | 5-(2-甲氧基苯基)噻唑-2-基 |
540 | 噻吩-2-基 | 5-(3-甲氧基苯基)噻唑-2-基 |
541 | 噻吩-2-基 | 5-(4-氟苯基)噻唑-2-基 |
542 | 噻吩-2-基 | 5-(2,4-二氟苯基)噻唑-2-基 |
543 | 噻吩-2-基 | 5-(3-甲氧基苄基)噻唑-2-基 |
544 | 噻吩-2-基 | 4-(3-甲氧基苯基)噻唑-2-基 |
545 | 噻吩-2-基 | 4-(4-氟苯基)噻唑-2-基 |
546 | 环丙基 | 4-(甲氧基羰基)噻唑-5-基 |
547 | 环丙基 | 4-[(2-甲氧基-2-氧乙基)氨基甲酰基]噻唑-5-基 |
548 | 环丙基 | 5-[1-N-(2-甲氧基-2-氧乙基)-1-H-吲哚-3-基]噁唑-2-基 |
549 | 环丙基 | 5-(2-甲氧基苯基)噁唑-2-基 |
550 | 环丙基 | 5-[(S)-1-(叔丁氧基羰基)-2-苯基乙基]噁唑-2-基 |
551 | 环丙基 | 5-[4-(甲基羧基)苯基]噁唑-2-基 |
552 | 环丙基 | 5-(3-甲氧基苄基)噁唑-2-基 |
553 | 环丙基 | 5-(4-苯基)噁唑-2-基 |
554 | 环丙基 | 5-(2-甲氧基苯基)噻唑-2-基 |
555 | 环丙基 | 5-(3-甲氧基苯基)噻唑-2-基 |
556 | 环丙基 | 5-(4-氟苯基)噻唑-2-基 |
557 | 环丙基 | 5-(2,4-二氟苯基)噻唑-2-基 |
558 | 环丙基 | 5-(3-甲氧基苄基)噻唑-2-基 |
559 | 环丙基 | 4-(3-甲氧基苯基)噻唑-2-基 |
560 | 环丙基 | 4-(4-氟苯基)噻唑-2-基 |
序号 | R2 | R3 | R1 |
561 | 甲基 | 氢 | 苯基 |
562 | 甲基 | 氢 | 苄基 |
563 | 甲基 | 氢 | 2-氟苯基 |
564 | 甲基 | 氢 | 3-氟苯基 |
565 | 甲基 | 氢 | 4-氟苯基 |
566 | 甲基 | 氢 | 2-氯苯基 |
567 | 甲基 | 氢 | 3-氯苯基 |
568 | 甲基 | 氢 | 4-氯苯基 |
569 | 乙基 | 氢 | 苯基 |
570 | 乙基 | 氢 | 苄基 |
571 | 乙基 | 氢 | 2-氟苯基 |
572 | 乙基 | 氢 | 3-氟苯基 |
573 | 乙基 | 氢 | 4-氟苯基 |
574 | 乙基 | 氢 | 2-氯苯基 |
575 | 乙基 | 氢 | 3-氯苯基 |
576 | 乙基 | 氢 | 4-氯苯基 |
577 | 噻吩-2-基 | 氢 | 苯基 |
578 | 噻吩-2-基 | 氢 | 苄基 |
579 | 噻吩-2-基 | 氢 | 2-氟苯基 |
580 | 噻吩-2-基 | 氢 | 3-氟苯基 |
581 | 噻吩-2-基 | 氢 | 4-氟苯基 |
582 | 噻吩-2-基 | 氢 | 2-氯苯基 |
583 | 噻吩-2-基 | 氢 | 3-氯苯基 |
584 | 噻吩-2-基 | 氢 | 4-氯苯基 |
Claims (26)
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US81673106P | 2006-06-27 | 2006-06-27 | |
US81673006P | 2006-06-27 | 2006-06-27 | |
US81682506P | 2006-06-27 | 2006-06-27 | |
US60/816,731 | 2006-06-27 | ||
US60/816,825 | 2006-06-27 | ||
US60/816,730 | 2006-06-27 | ||
PCT/US2007/014823 WO2008002570A2 (en) | 2006-06-27 | 2007-06-27 | Human protein tyrosine phosphatase inhibitors and methods of use |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101506180A CN101506180A (zh) | 2009-08-12 |
CN101506180B true CN101506180B (zh) | 2013-10-30 |
Family
ID=40977658
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2007800309846A Active CN101506180B (zh) | 2006-06-27 | 2007-06-27 | 人蛋白酪氨酸磷酸酶抑制剂及使用方法 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN101506180B (zh) |
ZA (1) | ZA200900492B (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0710645A2 (pt) | 2006-04-07 | 2012-03-20 | The Procter & Gamble Company | Anticorpos que se ligam à proteína humana tirosina fosfatase beta (hptpbeta) e usos dos mesmos |
US7622593B2 (en) | 2006-06-27 | 2009-11-24 | The Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
JP2013539756A (ja) * | 2010-10-07 | 2013-10-28 | アエルピオ セラピューティックス インコーポレイテッド | 眼球浮腫、血管新生および関連疾患を処置するための組成物および方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6596772B1 (en) * | 1999-08-27 | 2003-07-22 | Sugen, Inc. | Phosphate mimics and methods of treatment using phosphatase inhibitors |
-
2007
- 2007-06-27 CN CN2007800309846A patent/CN101506180B/zh active Active
-
2009
- 2009-01-21 ZA ZA200900492A patent/ZA200900492B/xx unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6596772B1 (en) * | 1999-08-27 | 2003-07-22 | Sugen, Inc. | Phosphate mimics and methods of treatment using phosphatase inhibitors |
Also Published As
Publication number | Publication date |
---|---|
ZA200900492B (en) | 2010-06-30 |
CN101506180A (zh) | 2009-08-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101506183B (zh) | 人蛋白酪氨酸磷酸酶抑制剂及其使用方法 | |
CN101506204B (zh) | 人蛋白酪氨酸磷酸酶抑制剂及使用方法 | |
ES2534392T3 (es) | Inhibidores de la proteína tirosina fosfatasa humana y métodos de uso | |
JP2009542659A5 (zh) | ||
JP2009542658A5 (zh) | ||
CN101506180B (zh) | 人蛋白酪氨酸磷酸酶抑制剂及使用方法 | |
RU2435763C2 (ru) | Ингибиторы тирозинфосфатазы белка человека и способы применения | |
AU2012200253B2 (en) | Human protein tyrosine phosphatase inhibitors and methods of use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: WARNER CHILCOTT CO., LTD. Free format text: FORMER OWNER: PROCTER + GAMBLE COMPANY Effective date: 20101101 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: OHIO STATE, UNITED STATES TO: FAJARDO, PUERTO RICO |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20101101 Address after: Puerto Rico Fajardo Applicant after: Warner Chicot Co.,Ltd. Address before: Ohio, USA Applicant before: THE PROCTER & GAMBLE Co. |
|
ASS | Succession or assignment of patent right |
Owner name: AIER PULUO MEDICAL CO., LTD. Free format text: FORMER OWNER: WARNER CHILCOTT CO., LTD. Effective date: 20121024 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20121024 Address after: Ohio, USA Applicant after: Elpro Medical Co.,Ltd. Address before: Puerto Rico Fajardo Applicant before: Warner Chicot Co.,Ltd. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee |
Owner name: AKEBIA THERAPEUTICS INC. Free format text: FORMER NAME: AERPIO THERAPEUTICS INC. |
|
CP01 | Change in the name or title of a patent holder |
Address after: Ohio, USA Patentee after: AKEBIA THERAPEUTICS Inc. Address before: Ohio, USA Patentee before: Elpro Medical Co.,Ltd. |
|
CP01 | Change in the name or title of a patent holder | ||
CP01 | Change in the name or title of a patent holder |
Address after: Ohio, USA Patentee after: Alpio treatment Co.,Ltd. Address before: Ohio, USA Patentee before: AKEBIA THERAPEUTICS Inc. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20210115 Address after: Ohio, USA Patentee after: Alpio pharmaceutical Co. Address before: Ohio, USA Patentee before: Alpio treatment Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20220426 Address after: Massachusetts Patentee after: Viewpoint pharmaceutical Co. Address before: Ohio, USA Patentee before: Alpio pharmaceutical Co. |